As clinical relevant result, we demonstrated resistance of early breast cancer with somatic PIK3CA-mutation to adjuvant aromatase inhibitor therapy, suggesting tamoxifen as preferred therapy in these patients. Here, CYP19A1 is linked to breast carcinoma.